Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
暂无分享,去创建一个
[1] C. Hoogenraad,et al. Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma , 2010, Human mutation.
[2] Martin J. Bent,et al. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta Neuropathologica.
[3] Bernd W Scheithauer,et al. The 2007 WHO Classification of Tumors of the Nervous System: Controversies in Surgical Neuropathology , 2008, Brain pathology.
[4] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[5] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[6] Andrey Korshunov,et al. Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.
[7] M. Wolter,et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status , 2011, International journal of cancer.
[8] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[9] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[10] P. Kleihues,et al. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.
[11] G. Reifenberger,et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.
[12] G. Reifenberger,et al. Molecular diagnostics of gliomas: state of the art , 2010, Acta Neuropathologica.
[13] David T. W. Jones,et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.
[14] H. Zentgraf,et al. Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.
[15] D. Louis,et al. Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma , 1995, Journal of neuropathology and experimental neurology.
[16] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[17] Pieter Wesseling,et al. IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group , 2010, Clinical Cancer Research.
[18] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[19] T. Tominaga,et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients , 2009, Cancer science.
[20] P. Kleihues,et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.
[21] C. Miller,et al. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Reifenberger,et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Kun-Liang Guan,et al. Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.
[24] S. Green,et al. Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.
[25] H. Zentgraf,et al. Monoclonal antibody specific for IDH1 R132H mutation , 2009, Acta Neuropathologica.
[26] G. Reifenberger,et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Christian Mawrin,et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.